Laurus Labs Ltd. (IN:LAURUSLABS)
:LAURUSLABS
Top Page
Laurus Labs Ltd.
(LAURUSLABS)
Select Model
Select Model
Rating:66Neutral
Price Target:
₹1,147.00
▲(3.61% Upside)
Action:ReiteratedDate:10/29/25
Laurus Labs' overall stock score is driven by strong technical momentum, despite overbought signals, and solid financial performance with revenue growth. However, high valuation metrics and cash flow challenges weigh on the score.
Positive Factors
Revenue Growth
Sustained double-digit revenue growth reflects expanding commercial traction across APIs, FDF and CDMO lines. Durable top-line expansion supports scale economics, funds reinvestment into capacity and R&D, and underpins medium-term earnings recovery if maintained.
Negative Factors
Negative Free Cash Flow
Persistent negative free cash flow driven by heavy capex limits the firm's ability to self-fund expansion or payouts. Over 2–6 months this raises refinancing and liquidity risk, constrains strategic flexibility and heightens sensitivity to any downturns in cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained double-digit revenue growth reflects expanding commercial traction across APIs, FDF and CDMO lines. Durable top-line expansion supports scale economics, funds reinvestment into capacity and R&D, and underpins medium-term earnings recovery if maintained.
Read all positive factors
Laurus Labs Ltd. (LAURUSLABS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹544.88B
Dividend Yield0.15%
Average Volume (3M)107.31K
Price to Earnings (P/E)59.4
Beta (1Y)1.08
Revenue Growth25.83%
EPS Growth421.20%
CountryIN
Employees6,007
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4.70
Shares Outstanding539,856,570
10 Day Avg. Volume186,027
30 Day Avg. Volume107,314
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)7.23
Price to Sales (P/S)5.82
P/FCF Ratio-821.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,225.00Price Target Upside10.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)16.05
Revenue Forecast (FY)₹68.38B
Laurus Labs Ltd. Business Overview & Revenue Model
Company Description
Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and a...
How the Company Makes Money
Laurus Labs generates revenue through multiple streams, primarily from the sale of active pharmaceutical ingredients (APIs) and finished formulations. The company has a robust client base that includes major pharmaceutical companies globally, whic...
Laurus Labs Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
65
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 63.58B | 55.54B | 50.41B | 60.41B | 49.36B | 48.14B |
| Gross Profit | 32.18B | 29.65B | 25.01B | 31.81B | 26.87B | 26.14B |
| EBITDA | 14.81B | 10.34B | 7.63B | 16.06B | 14.18B | 15.50B |
| Net Income | 6.84B | 3.58B | 1.61B | 7.90B | 8.28B | 9.84B |
Balance Sheet | ||||||
| Total Assets | 94.15B | 93.36B | 83.87B | 76.60B | 69.68B | 57.51B |
| Cash, Cash Equivalents and Short-Term Investments | 633.80M | 1.44B | 1.42B | 484.60M | 759.40M | 484.60M |
| Total Debt | 22.12B | 27.64B | 25.77B | 20.15B | 17.77B | 14.82B |
| Total Liabilities | 44.82B | 47.33B | 42.71B | 36.12B | 36.09B | 31.50B |
| Stockholders Equity | 48.05B | 44.73B | 41.11B | 40.38B | 33.51B | 25.98B |
Cash Flow | ||||||
| Free Cash Flow | 6.04B | -393.50M | -126.20M | 37.40M | 342.60M | 442.30M |
| Operating Cash Flow | 10.93B | 6.02B | 6.66B | 9.94B | 9.11B | 7.33B |
| Investing Cash Flow | -4.77B | -6.82B | -8.22B | -9.96B | -9.14B | -9.41B |
| Financing Cash Flow | -6.68B | 392.80M | 2.50B | -266.40M | 302.60M | 2.55B |
Laurus Labs Ltd. Technical Analysis
Positive
1107.05
Price Trends
1012.62
Negative
1020.68
Negative
926.83
Positive
Market Momentum
-8.74
Negative
50.20
Neutral
67.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LAURUSLABS, the sentiment is Positive. The current price of 1107.05 is above the 20-day moving average (MA) of 1015.78, above the 50-day MA of 1012.62, and above the 200-day MA of 926.83, indicating a neutral trend. The MACD of -8.74 indicates Negative momentum. The RSI at 50.20 is Neutral, neither overbought nor oversold. The STOCH value of 67.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:LAURUSLABS.
Laurus Labs Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹401.71B | 27.58 | ― | 0.28% | 9.66% | 25.79% | |
66 Neutral | ₹544.88B | 59.42 | ― | 0.15% | 25.83% | 421.20% | |
63 Neutral | ₹599.31B | 91.56 | ― | 0.12% | 10.62% | -66.88% | |
61 Neutral | ₹284.82B | 27.13 | ― | 1.07% | -1.51% | 14.27% | |
53 Neutral | ₹612.52B | 35.61 | ― | 0.24% | 30.27% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:LAURUSLABS
Laurus Labs Ltd.
1,009.30
412.26
69.05%
IN:BIOCON
Biocon Limited
370.10
31.40
9.27%
IN:GLAND
Gland Pharma Ltd.
1,728.75
188.05
12.21%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,170.50
665.44
44.21%
IN:IPCALAB
IPCA Laboratories Limited
1,583.65
192.38
13.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.